Group A Streptococcus Molecular Point of Care testing in a Paediatric Emergency Department

This pilot study in a London paediatric emergency department suggests that implementing a molecular point-of-care test for Group A Streptococcus could significantly reduce unnecessary antibiotic prescribing and enable immediate clinical decision-making, despite a low infection prevalence during the study period.

The Gist

Imagine a busy pediatric emergency room (ED) as a bustling train station. Every day, hundreds of children arrive with sore throats, fevers, or rashes. The doctors are the station masters trying to figure out: Is this a minor delay caused by a virus (like a slow train), or is it a serious blockage caused by a bacteria called Group A Strep (like a broken track that needs immediate repair)?

For years, the rule in the UK has been: "Don't test everyone; just guess based on how sick they look." If the guess looks bad, they give antibiotics (the repair crew). If it looks okay, they wait. But recently, there was a massive surge in Strep infections, and the "guessing game" started to feel risky. Doctors were either giving antibiotics too often (wasting resources and creating resistance) or waiting too long to treat the kids who actually needed help.

This paper is like a pilot test for a "Super-Speed Detector" to see if it could help the station masters make better decisions.

The Experiment: The "Magic Swab" vs. The "Slow Lab"

The researchers set up a small experiment in a London hospital. When a doctor took a throat swab from a child to send to the regular lab (the "Slow Lab"), the research team asked if they could take a second swab just for their study.

• The Slow Lab (Standard Culture): This is like sending a letter by post. You drop it off, and you have to wait 3 to 5 days (sometimes up to a week!) to get a reply. If the letter says "Strep found," the doctor might call the family back to start antibiotics. But by then, the child has been sick for days.
• The Magic Swab (Molecular POCT): This is like having a super-fast scanner right at the station. It looks for the DNA of the bacteria and gives an answer in minutes.

Crucially, the doctors didn't know the results of the "Magic Swab" while treating the kids. They treated the children based on their usual rules. The researchers just watched to see what would have happened if they had used the Magic Swab.

What They Found: The "False Alarm" Problem

Here is the big surprise they discovered:

1. The "Over-Prescribing" Issue: Out of 49 children who had throat swabs, 38 of them (77%) were given antibiotics.

   • The Metaphor: Imagine the station masters were handing out "emergency repair kits" to almost everyone, just in case.
   • The Reality: When the researchers checked the "Magic Swab" results later, they found that 29 of those 38 children did NOT have Strep. They were given antibiotics unnecessarily. If the doctors had seen the instant "Negative" result from the Magic Swab, they could have saved those kids from taking medicine they didn't need.

2. The "Too Slow" Issue: Only 6 children actually had Strep.

   • The Metaphor: These were the kids with the broken tracks.
   • The Reality: One child had to be called back 3 days later because the "Slow Lab" took too long to send the letter. If the "Magic Swab" had been used, the doctor would have known immediately and started the repair crew right away.

3. The "Scorecard" Didn't Work Well: Doctors usually use a scorecard (FeverPAIN or Centor score) to guess if it's Strep. In this group of kids, the scorecard was unreliable. Many kids with low scores still got antibiotics because the doctors were worried, and many with high scores turned out to be negative. The "Magic Swab" cut through the confusion.

The Bottom Line: Why This Matters

Think of this study as a dress rehearsal for a new way of running the station.

• The Good News: The "Magic Swab" is fast, easy to use, and incredibly good at saying "No, this child is fine, no antibiotics needed." This could stop the overuse of antibiotics, which is a huge problem in medicine (like using a sledgehammer to crack a nut).
• The Catch: The test costs money, and right now, the UK guidelines say "don't test." But this study suggests that during times of high infection (like the 2022-2023 surge), having a "Super-Speed Detector" could save time, stop unnecessary medicine, and get the right kids the right treatment instantly.

In simple terms: The study shows that if doctors had a tool to instantly rule out Strep, they could stop giving antibiotics to three out of every four kids who don't need them, while making sure the few kids who do need them get treated immediately, rather than waiting days for a lab result. It's about swapping "guessing and waiting" for "knowing and acting."

Technical Summary

1. Problem Statement

• Clinical Context: In England and Wales, national guidance (NICE) generally advises against diagnostic testing for sore throats in children over 5, favoring syndromic scoring systems (FeverPAIN, Centor) to guide antibiotic prescribing. However, these scoring systems have uncertain value in younger children (<5 years).
• The Surge: A significant upsurge in Streptococcus pyogenes (Group A Strep) infections occurred in 2022–2023, leading to increased scarlet fever notifications, invasive infections, and a sharp rise in Emergency Department (ED) attendances for sore throat (+953%).
• The Gap: Conventional throat culture, the current standard, takes 3–5 days to yield results. This delay often leads to empiric antibiotic prescribing (to cover potential bacterial infection) or delayed treatment confirmation, contributing to high antibiotic usage rates and potential antimicrobial resistance.
• Objective: To evaluate the feasibility and potential clinical impact of using a rapid molecular POCT to detect S. pyogenes DNA in a paediatric ED setting, specifically to determine if it could optimize management and reduce unnecessary antibiotic prescribing.

2. Methodology

• Study Design: A pilot research and feasibility study conducted in a paediatric ED at Imperial College Healthcare NHS Trust (West London).
• Timeline: May 25, 2023 – June 25, 2025 (Note: The study was terminated early after 50 recruits due to a reduction in swabbing practices following the re-instatement of NICE guidelines in Feb 2023).
• Participants: Children <16 years presenting with acute febrile syndromes where a clinician requested a routine throat swab for culture.
• Procedure:
  • Dual Swabbing: Participants provided a routine clinical swab (sent for standard culture/MALDI-TOF) and a second research-only swab.
  • POCT Method: The research swab was processed immediately using the Abbott ID Now molecular POCT platform.
  • Blinding: Crucially, the POCT results were not shared with treating clinicians. Clinical management (antibiotic prescribing) was based solely on clinical judgment and the pending culture results. This allowed researchers to compare actual prescribing habits against what would have happened if POCT results were available.
• Data Collection: Demographics, FeverPAIN/Centor scores, ED stay duration, antibiotic prescriptions, and time-to-result for both culture and POCT.

3. Key Contributions

• Feasibility Demonstration: Proved that molecular POCT can be easily integrated into a busy paediatric ED workflow, with results generated within minutes compared to days for culture.
• Quantification of Over-prescribing: Provided empirical data suggesting that a significant portion of antibiotic prescriptions in this cohort were driven by suspicion of GAS despite negative or pending culture results.
• Discordance Analysis: Investigated discrepancies between molecular POCT (DNA detection) and culture, highlighting the potential of POCT to detect pathogen DNA even when cultures are negative (e.g., due to prior antibiotic use or sampling variance).
• Policy Relevance: Offered evidence to challenge the current "no-testing" paradigm in the UK during periods of high GAS prevalence, suggesting a role for "rule-out" testing.

4. Key Results

• Cohort: 49 children were included in the final analysis (average age 5.8 years).
• Prevalence: The prevalence of confirmed S. pyogenes via culture was low (12.8%; 6/47 symptomatic children), reflecting the tail end of the 2022–2023 surge.
• Antibiotic Prescribing:
  • Overall: 77.6% (38/49) of children received antibiotics.
  • Negative Culture Group: Among the 41 children with negative cultures, 31 (75.6%) still received antibiotics.
  • POCT Impact: Of the 31 children with negative cultures who received antibiotics, 27 (87.1%) also had a negative molecular POCT. The authors estimate these children could have avoided antibiotics entirely if the POCT result had been available and acted upon.
• Time to Result:
  • Culture: Mean time 3.67 days (range 3–5 days).
  • POCT: Results available within minutes.
  • Clinical Consequence: One child with a positive culture was recalled 3 days later to start antibiotics after an initial negative clinical assessment, illustrating the delay caused by culture.
• Discordance:
  • 5 cases were POCT-positive but culture-negative.
  • The authors suggest these may be "true positives" where DNA was detected despite a negative culture (possibly due to prior antibiotic use or sampling differences), rather than false positives.
  • Only 1 case of indeterminate POCT result occurred (due to software needs).
• Scoring Systems: FeverPAIN and Centor scores showed limited predictive value in this cohort, with many children having low scores yet still being swabbed and prescribed antibiotics.

5. Significance and Conclusion

• Antibiotic Stewardship: The study suggests that implementing a "rule-out" molecular POCT in the paediatric ED could reduce unnecessary antibiotic prescribing by over 75% in cases where GAS suspicion is the primary driver.
• Timely Decision Making: Immediate results enable clinicians to confidently withhold antibiotics in negative cases or start targeted therapy in positive cases without the 3–5 day wait associated with culture.
• Outbreak Control: Rapid identification of positive cases is critical for managing potential outbreaks and preventing transmission, a feature culture cannot provide in real-time.
• Future Directions: While the cost of molecular POCT is higher than antigen tests, the study argues that the benefits in reducing transmission, optimizing prescribing, and improving patient flow warrant further economic analysis and larger-scale trials. The authors note that parental willingness to participate increased when the potential for immediate diagnostic feedback was highlighted.

Limitations: The study was a pilot with a small sample size (terminated early), and the POCT results were not used for clinical decision-making, meaning the actual reduction in prescribing is theoretical based on the data collected. Additionally, the low prevalence of GAS during the study period may limit generalizability to peak outbreak seasons.